Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-26T13:16:35.064Z Has data issue: false hasContentIssue false
  • English
  • Français

Ocular Pigmentation, Extrapyramidal Symptoms and Phenothiazine Dosage

Published online by Cambridge University Press:  29 January 2018

R. H. Wheeler ,
V. R. Bhalerao  and
M. J. Gilkes
R. H. Wheeler
Affiliation:
St. Francis Hospital, Haywards Heath, Sussex
V. R. Bhalerao
Affiliation:
St. Francis Hospital, Haywards Heath, Sussex
M. J. Gilkes
Affiliation:
St. Francis Hospital, Haywards Heath, Sussex
Get access Rights & Permissions [Opens in a new window]

Extract

Oculo-cutaneous pigmentation has often been reported (Brit med. J., 1967) in patients receiving heavy doses of phenothiazines. This paper sets out to investigate, (a) the incidence of ocular pigmentation in such patients; (b) whether the measures suggested by Valentine and Jardine (1966) for minimizing this complication are effective; (c) the relationship of ocular pigmentation to extrapyramidal symptoms (and hence whether the pigmentation can be regarded as a sign of brain damage).

Type
Pharmacotherapy
Information
The British Journal of Psychiatry , Volume 115 , Issue 523 , June 1969 , pp. 687 - 690
Copyright
Copyright © Royal College of Psychiatrists, 1969 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barnes, G. J., and Cameron, M. E. (1966). “Skin and eye changes associated with chlorpromazinc therapy.” Med. J. Aus., 1, 478.CrossRefGoogle Scholar
Barsa, J. A., Newton, J. C., and Saunders, J. C. (1965). “Lenticular and corneal opacities during phenothiazine therapy.” J. Amer, med. Ass., 193, 10.Google Scholar
Bock, R., and Swain, J. (1963). “Ophthalmologic findings in patients on long-term chlorpromazine therapy.” Amer. J. Ophthal., 56, 808.CrossRefGoogle Scholar
Brit. med. J. (1967), ii, 630. “Chlorpromazine melanosis.”Google Scholar
Cairns, R. J., Capoore, H. S., and Gregory, I. D. R. (1965). “Oculocutaneous changes after years on high doses of chlorpromazine.” Lancet, i, 239.CrossRefGoogle Scholar
DeLong, S. L., Poley, B. J., and McFarlane, J. R. (1965). “Ocular changes associated with long-term chlorpromazine therapy.” Arch. Ophthal., 73, 611.Google Scholar
Galbraith, J. E. K., Gibson, B. H. L., Crock, G. W., and Pearce, T. A. A. (1966). “The Mont Park survey for ocular changes in chlorpromazine therapy.” Med. J. Aust., 1, 481.CrossRefGoogle Scholar
Greiner, A. C., and Berry, K. (1964). “Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy.” Canad. med. Ass. J., 90, 663.Google Scholar
Margolis, L. H., and Goble, J. L. (1965). “Lenticular opacities with prolonged phenothiazine therapy—a potential hazard with all phenothiazine derivatives.” J. Amer. med. Ass., 193, 7.CrossRefGoogle Scholar
Mathalone, M. B. R. (1965). “Oculocutaneous effects of chlorpromazine.” Lancet, ii, 111.Google Scholar
Mathalone, M. B. R. (1967). “Eye and skin changes in psychiatric patients treated with chlorpromazine.” Brit. J. Ophthal., 51, 86.CrossRefGoogle Scholar
Siddall, J. R. (1965). “The ocular-toxic findings with prolonged and high dosage chlorpromazine intake.” Arch. Ophthal., 74, 460.Google Scholar
Valentine, M., and Jardine, P. (1966). “Phenothiazines and eye complications.” Brit. med. J., ii, 586.CrossRefGoogle Scholar
Wetterholm, D. H., Snow, H. L., and Winter, F. C. (1965). “A clinical study of pigmentary changes in cornea and lens in chronic chlorpromazine therapy.” Arch. Ophthal., 74, 55.Google Scholar
Zelickson, A. S., and Zeller, H. C. (1964). “A new and unusual reaction to chlorpromazine.” J. Amer. med. Ass., 188, 394.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.